Related Experiment Videos
Malignant fibrous histiocytoma
The Australian and New Zealand Journal of Surgery
|October 1, 1980
Summary
Malignant fibrous histiocytoma, even in advanced stages, shows a good prognosis. Radiotherapy demonstrated effectiveness in managing primary lesions and pulmonary metastases, indicating potential for improved patient outcomes.
Area of Science:
- Oncology
- Pathology
- Radiology
Background:
- Malignant fibrous histiocytoma (MFH) is an uncommon soft tissue sarcoma.
- Unusual primary sites like the scrotum and small-gut mesentery present diagnostic challenges.
- Advanced disease and metastatic spread are often associated with poor prognoses in many cancers.
Purpose of the Study:
- To report on seven cases of malignant fibrous histiocytoma.
- To evaluate the biological behavior and treatment outcomes of MFH.
- To assess the efficacy of radiotherapy in managing MFH, including metastatic disease.
Main Methods:
- Retrospective case series analysis of seven patients diagnosed with malignant fibrous histiocytoma.
- Review of histogenesis, biological behavior, and treatment modalities.
- Assessment of treatment response, particularly to radiotherapy, in primary and metastatic lesions.
Main Results:
- Two cases involved unusual primary sites: scrotum and small-gut mesentery.
- Three patients with pulmonary metastases survived for five years post-metastasis.
- Radiotherapy controlled the primary lesion in one patient and was effective for pulmonary metastases in three patients.
Conclusions:
- Malignant fibrous histiocytoma may have a favorable prognosis even with advanced or metastatic disease.
- These tumors demonstrate a response to radiotherapy, suggesting its therapeutic value.
- Further evaluation is needed for the prophylactic use of radiotherapy and chemotherapy in MFH management.